LLY

818

-0.07%↓

JNJ

154.85

-1.31%↓

ABBV

190.47

-0.06%↓

NVO

76.8

-3.69%↓

UNH

305.9

-2.35%↓

LLY

818

-0.07%↓

JNJ

154.85

-1.31%↓

ABBV

190.47

-0.06%↓

NVO

76.8

-3.69%↓

UNH

305.9

-2.35%↓

LLY

818

-0.07%↓

JNJ

154.85

-1.31%↓

ABBV

190.47

-0.06%↓

NVO

76.8

-3.69%↓

UNH

305.9

-2.35%↓

LLY

818

-0.07%↓

JNJ

154.85

-1.31%↓

ABBV

190.47

-0.06%↓

NVO

76.8

-3.69%↓

UNH

305.9

-2.35%↓

LLY

818

-0.07%↓

JNJ

154.85

-1.31%↓

ABBV

190.47

-0.06%↓

NVO

76.8

-3.69%↓

UNH

305.9

-2.35%↓

Search

Actinium Pharmaceuticals Inc

Open

1.51 1.34

Overview

Share price change

24h

Current

Min

1.43

Max

1.54

Key metrics

By Trading Economics

Income

-9.3M

-16M

EPS

-0.51

Employees

31

EBITDA

-9.3M

-17M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+302.68% upside

Dividends

By Dow Jones

Next Earnings

1 sie 2025

Market Stats

By TradingEconomics

Market Cap

12M

61M

Previous open

0.17

Previous close

1.51

Actinium Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

15 cze 2025, 23:40 UTC

Acquisitions, Mergers, Takeovers

Santos Gets $18.72 Billion Takeover Offer From Adnoc-Led Consortium -- 2nd Update

15 cze 2025, 23:27 UTC

Acquisitions, Mergers, Takeovers

Santos Gets $18.72 Billion Takeover Offer From Adnoc-Led Consortium -- Update

15 cze 2025, 23:10 UTC

Acquisitions, Mergers, Takeovers

Santos Gets $18.72 Billion Takeover Offer From Adnoc-Led Consortium

13 cze 2025, 22:33 UTC

Acquisitions, Mergers, Takeovers

Millicom to Acquire Telefonica Ecuador for $380 Million

15 cze 2025, 23:50 UTC

Market Talk

Gold Edges Higher Amid Likely Safe-Haven Demand -- Market Talk

15 cze 2025, 23:47 UTC

Market Talk

Nikkei May Trade Rangebound Amid Uncertainty Over Middle East -- Market Talk

15 cze 2025, 23:41 UTC

Market Talk

Oil Rises Amid Middle East Tensions -- Market Talk

15 cze 2025, 23:33 UTC

Market Talk

China Most Affected by Any Disruption to Iran Crude Oil Exports -- Market Talk

15 cze 2025, 23:29 UTC

Market Talk

Oil Price Could Rise More This Week -- Market Talk

15 cze 2025, 23:27 UTC

Market Talk

Fed's Powell Likely to Emphasize Ongoing Policy Patience -- Market Talk

15 cze 2025, 23:27 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 cze 2025, 23:02 UTC

Market Talk

Global Energy Roundup: Market Talk

15 cze 2025, 23:02 UTC

Market Talk

Rising Middle East Tensions Could Be Passing Storm for World Economy -- Market Talk

15 cze 2025, 22:47 UTC

Acquisitions, Mergers, Takeovers

Santos Says Recommendation Requires Independent Expert Concluding Offer Is Fair, Reasonable

15 cze 2025, 22:47 UTC

Acquisitions, Mergers, Takeovers

Santos Intends to Recommend Shareholders Vote In Favor of Transaction If Binding Offer Made

15 cze 2025, 22:46 UTC

Acquisitions, Mergers, Takeovers

Santos Intends to Negotiate Terms of Process, Exclusivity Deed With XRG Consortium

15 cze 2025, 22:46 UTC

Acquisitions, Mergers, Takeovers

Santos to Give XRG Consortium Due Diligence Access

15 cze 2025, 22:45 UTC

Acquisitions, Mergers, Takeovers

Santos Says XRG Consortium Offer Is Final, Had Made Two Earlier Proposals

15 cze 2025, 22:45 UTC

Acquisitions, Mergers, Takeovers

Santos Says XRG Consortium Offering A$8.89/Share in Cash

15 cze 2025, 22:44 UTC

Acquisitions, Mergers, Takeovers

Santos Says XRG Consortium Includes Abu Dhabi Development Holding Co and Carlyle

15 cze 2025, 22:44 UTC

Acquisitions, Mergers, Takeovers

Santos Gets Takeover Offer From Consortium Led by Abu Dhabi's Adnoc

15 cze 2025, 22:31 UTC

Market Talk

Gold Price Can Push Toward New All-Time High -- Market Talk

14 cze 2025, 01:24 UTC

Acquisitions, Mergers, Takeovers

Nippon to Close U.S. Steel Deal After National-Security Pact With Trump -- 3rd Update

13 cze 2025, 23:50 UTC

Acquisitions, Mergers, Takeovers

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- 2nd Update

13 cze 2025, 23:20 UTC

Acquisitions, Mergers, Takeovers

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- Update

13 cze 2025, 23:09 UTC

Acquisitions, Mergers, Takeovers

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- WSJ

13 cze 2025, 23:03 UTC

Acquisitions, Mergers, Takeovers

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal --WSJ

13 cze 2025, 22:18 UTC

Acquisitions, Mergers, Takeovers

Millicom to Acquire Telefonica Ecuador for $380M

13 cze 2025, 22:04 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Better Data Facilitate Investments In Oil Patch -- Market Talk

13 cze 2025, 21:42 UTC

Acquisitions, Mergers, Takeovers

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

Peer Comparison

Price change

Actinium Pharmaceuticals Inc Forecast

Price Target

By TipRanks

302.68% upside

12 Months Forecast

Average 6 USD  302.68%

High 9 USD

Low 4 USD

Based on 3 Wall Street analysts offering 12 month price targets forActinium Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

3

Buy

0

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.